Volume 8, Issue 1 (1-2020)                   JoMMID 2020, 8(1): 1-6 | Back to browse issues page

DOI: 10.29252/JoMMID.8.1.1

XML Print

Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran
Abstract:   (217 Views)
Introduction: A new pathological form of HCV named as occult HCV infection (OCI) has been recently characterized by the presence of HCV RNA in liver biopsy and/or peripheral blood mononuclear cell specimens (PBMCs) and the absence of detectable circulating HCV RNA in plasma samples. In this study, we investigated the presence of HCV RNA in PBMCs and plasma samples of 100 hemophilia patients with negative serum HCV RNA. Methods: One hundred hemophilia participants receiving IFN-free direct-acting antivirals (DAAs) regimens as a treatment of HCV infection participated in this study. PBMCs were separated with Ficoll before RNA extraction. The HCV genotypes of the positive specimens were also analyzed by RT-PCR assay. Finally, data analysis was performed by SPSS software. Results: Our data revealed that out of 100 hemophilia patients, three (3%, 95% CI: 0.006-0.085) were positive for OCI, showing a significant association between OCI and genotype3/drug regimens (p = 0.0203). There was no significant increase at ALT and AST levels in patients with OCI. Moreover, a genotype difference was observed between plasma and PBMCs samples of 1% (1/100) of patients. Conclusion: Generally, HCV genotyping in PBMCs along with plasma subtyping before beginning the therapy is vital due to the possibility of OCI detection.
Full-Text [PDF 382 kb]   (65 Downloads)    
Type of Study: Original article | Subject: Infectious diseases and public health
Received: 2020/04/27 | Accepted: 2020/01/11 | Published: 2020/01/11

1. Kaźmierczak J, Pawełczyk A, Cortes KC, Radkowski M. Seronegative hepatitis C virus infection. Arch Immunol Ther Exp. 2014; 62 (2): 145-151. [DOI:10.1007/s00005-013-0257-7]
2. Farahani M, Bokharaei‐Salim F, Ghane M, Basi A, Meysami P, Keyvani H. Prevalence of occult hepatitis C virus infection in Iranian patients with lymphoproliferative disorders. J Med Virol. 2013; 85 (2): 235-240. [DOI:10.1002/jmv.23460]
3. Helaly GF, Elsheredy AG, Mousa AAEB, Ahmed HKF, Oluyemi AE-GS. Seronegative and occult hepatitis C virus infections in patients with hematological disorders. Arch Virol. 2017; 162 (1): 63-69. [DOI:10.1007/s00705-016-3049-7]
4. Mousavi SH, Khairkhah N, Bahri TD, Anvar A, Saraji AA, Behnava B, et al. First report of prevalence of blood-borne viruses (HBV, HCV, HIV, HTLV-1 and Parvovirus B19) among hemophilia patients in Afghanistan. Sci Rep. 2019; 9 (1): 7259. [DOI:10.1038/s41598-019-43541-8]
5. Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017; 14 (2): 122. [DOI:10.1038/nrgastro.2016.176]
6. Lohmann V, Hoffmann S, Herian U, Penin F, Bartenschlager R. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J Virol. 2003; 77 (5): 3007-19. [DOI:10.1128/JVI.77.5.3007-3019.2003]
7. Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother. 2009; 65 (2): 202-12. [DOI:10.1093/jac/dkp388]
8. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010; 138 (2): 447-62. [DOI:10.1053/j.gastro.2009.11.055]
9. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49 (4): 1335-74. [DOI:10.1002/hep.22759]
10. Martinot‐Peignoux M, Stern C, Maylin S, Ripault MP, Boyer N, Leclere L, et al. Twelve weeks posttreatment follow‐up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology. 2010; 51 (4): 1122-6. [DOI:10.1002/hep.23444]
11. Kapadia SN, Johnson P, Schackman BR, Bao Y. Hepatitis C treatment uptake by new prescribers after the introduction of direct acting antivirals. J Gen Intern Med. 2019; 1-3. [DOI:10.1007/s11606-019-05200-6]
12. Kapadia SN, Marks KM. Hepatitis C management simplification from test to cure: a framework for primary care providers. Clin Ther. 2018; 40 (8): 1234-45. [DOI:10.1016/j.clinthera.2018.05.010]
13. Shah N, Pierce T, Kowdley KV. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Expert Opin Investig Drugs. 2013; 22 (9): 1107-21. [DOI:10.1517/13543784.2013.806482]
14. D'Ambrosio R, Della Corte C, Colombo M. Hepatocellular carcinoma in patients with a sustained response to anti-hepatitis C therapy. Int J Mol Sci. 2015; 16 (8): 19698-712. [DOI:10.3390/ijms160819698]
15. Bastani MN, Keyvani H, Esghaei M, Monavari SH, Ebrahimi M, Garshasebi S, et al. Prevalence of occult hepatitis C virus infection in Iranian patients with beta thalassemia major. Arch Virol. 2016; 161 (7): 1899-906. [DOI:10.1007/s00705-016-2862-3]
16. Castillo I, Pardo M, Bartolomé J, Rodríguez-Iñigo E, Lucas SD, Salas C, et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. The J Infect Dis. 2004; 189 (1): 7-14. [DOI:10.1086/380202]
17. Castillo I, Rodriguez-Inigo E, Bartolome J, De Lucas S, Ortiz-Movilla N, Lopez-Alcorocho J. Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection. Gut. 2005; 54 (5): 682-685. [DOI:10.1136/gut.2004.057281]
18. Castillo I, Rodríguez-Iñigo E, López-Alcorocho JM, Pardo M, Bartolomé J, Carreño V. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis. 2006; 43 (10): 1277-83. [DOI:10.1086/508198]
19. Yousif MM, Elsadek Fakhr A, Morad EA, Kelani H, Hamed EF, Elsadek HM. Prevalence of occult hepatitis C virus infection in patients who achieved sustained virologic response to direct-acting antiviral agents. Infez Med. 2018; 26 (3): 237-43.
20. Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Diagnosis of occult hepatitis C without the need for a liver biopsy. J Med Virol. 2010; 82 (9): 1554-9 [DOI:10.1002/jmv.21866]
21. Bokharaei‐Salim F, Keyvani H, Monavari SHR, Alavian SM, Madjd Z, Toosi MN. Occult hepatitis C virus infection in Iranian patients with cryptogenic liver disease. J Med Virol. 2011; 83 (6): 989-95. [DOI:10.1002/jmv.22044]
22. Barril G, Castillo I, Arenas MD, Garcia-Valdecasas J, Garcia-Fernandez N, Gonzalez-Parra E, et al. Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol. 2008; 19 (12): 2288-92. [DOI:10.1681/ASN.2008030293]
23. Thongsawat S, Maneekarn N, Kuniholm MH, Thungsuputi A, Lumlertkul D, Bannachak D, et al. Occult hepatitis C virus infection during an outbreak in a hemodialysis unit in Thailand. J Med Virol. 2008; 80 (5): 808-15. [DOI:10.1002/jmv.21126]
24. Youssef SS, Nasr AS, El Zanaty T, Rawi E, Sayed R, Mattar MM. Prevalence of occult hepatitis C virus in egyptian patients with chronic lymphoproliferative disorders. Hepat Res Treat. 2012; 2012: 1-6 [DOI:10.1155/2012/429784]
25. Baid-Agrawal S, Schindler R, Reinke P, Staedtler A, Rimpler S, Malik B. Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients. J Hepatol. 2014; 60 (5): 928-33. [DOI:10.1016/j.jhep.2014.01.012]
26. Keyvani H, Bokharaei-Salim F, Monavari SH, Esghaei M, Toosi MN, Fakhim S. Occult hepatitis C virus infection in candidates for liver transplant with cryptogenic cirrhosis. Hepatitis Monthly. 2013; 13 (8): e11290 [DOI:10.5812/hepatmon.11290]
27. Castillo I, Martinez-Ara J, Olea T, Madero R, Hernández E, Bernis C, et al. High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies. Kidney Int. 2014; 86 (3): 619-24. [DOI:10.1038/ki.2014.68]
28. De Marco L, Manzini P, Trevisan M, Danielle F, Balloco C, Pizzi A, et al. Prevalence and follow-up of occult HCV infection in an Italian population free of clinically detectable infectious liver disease. PLoS One. 2012; 7 (8): e43541. [DOI:10.1371/journal.pone.0043541]
29. Gatserelia L, Sharvadze L, Karchava M, Dolmazashvili E, Tsertsvadze T. Occurrence of occult HCV infection among Hiv infected patients in Georgia. Georgian Med News. 2014; 226: 37-41.
30. De Marco L, Gillio-Tos A, Fiano V, Ronco G, Krogh V, Palli D. Occult HCV infection: an unexpected finding in a population unselected for hepatic disease. PLoS One. 2009; 4 (12): e8128. [DOI:10.1371/journal.pone.0008128]
31. Bigaud M, Maurer C, Vedrine C, Puissant B, Blancher A. A simple method to optimize peripheral blood mononuclear cell preparation from cynomolgus monkeys and improve mixed lymphocyte reactions. J Pharmacol Toxicol Methods. 2004; 50 (2): 153-9. [DOI:10.1016/j.vascn.2004.04.003]
32. Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 1997; 35 (1): 201-7. [DOI:10.1128/JCM.35.1.201-207.1997]
33. Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol. 2004; 78 (11): 5867-74. [DOI:10.1128/JVI.78.11.5867-5874.2004]
34. Barril G, Castillo I, Arenas MD, Espinosa M, Garcia-Valdecasas J, Garcia-Fernandez N. Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol. 2008; 19 (12): 2288-92. [DOI:10.1681/ASN.2008030293]
35. Rutter K, Hofer H, Beinhardt S, Dulic M, Gschwantler M, Maieron A. Durability of SVR in chronic hepatitis C patients treated with peginterferon‐α2a/ribavirin in combination with a direct‐acting antiviral. Aliment Pharmacol Ther. 2013; 38 (2): 118-23. [DOI:10.1111/apt.12350]
36. Moor AC, Dubbelman TM, VanSteveninck J, Brand A. Transfusion‐transmitted diseases: risks, prevention and perspectives. Eur J Haematol. 1999; 62 (1): 1-18. [DOI:10.1111/j.1600-0609.1999.tb01108.x]
37. Abdelrahim SS, Khairy R, Esmail MAM, Ragab M, Abdel‐Hamid M, Abdelwahab SF. Occult hepatitis C virus infection among Egyptian hemodialysis patients. J Med Virol. 2016; 88 (8): 1388-93. [DOI:10.1002/jmv.24467]
38. Naghdi R, Ranjbar M, Bokharaei-Salim F, Keyvani H, Savaj S, Ossareh S. Occult hepatitis C infection among hemodialysis patients: A prevalence study. Ann Hepatol. 2017; 16 (4): 510-3. [DOI:10.5604/01.3001.0010.0277]
39. Carreño V. Seronegative occult hepatitis C virus infection: Clinical implications. J Clin Virol. 2014; 61 (3): 315-20. [DOI:10.1016/j.jcv.2014.09.007]
40. Carreño V, Bartolomé J, Castillo I, Quiroga JA. New perspectives in occult hepatitis C virus infection. World J Gastroenterol. 2012; 18 (23): 2887. [DOI:10.3748/wjg.v18.i23.2887]
41. Wang Y, Rao H, Chi X, Li B, Liu H, Wu L, et al. Detection of residual HCV RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality. EBioMedicine. 2019; 46: 227-235. [DOI:10.1016/j.ebiom.2019.07.043]